^
Association details:
| Biomarker: | TROP2 expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | DM001 (Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1152 DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models
Published date:
11/04/2023
Excerpt:
In vitro, DM001 demonstrated high affinity and cytotoxicity in multiple cell lines expressing TROP2 and EGFR, with preferential binding to cells expressing both antigens. In vivo, DM001 exhibited potent, dose-dependent efficacy in multiple cell line and patient-derived xenografts when compared to benchmarks. Notably, DM001 efficacy was superior to parental ADCs in patient-derived lung and pancreatic xenograft models.
DOI:
http://dx.doi.org/10.1136/jitc-2023-SITC2023.1152
